Brii Biosciences Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported net loss was CNY 347.59 million compared to CNY 2,953.18 million a year ago. Basic loss per share from continuing operations was CNY 0.48 compared to CNY 14.86 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 HKD | +5.51% | +3.08% | -41.23% |
May. 15 | Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China | MT |
Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.23% | 119M | |
+8.90% | 114B | |
+11.47% | 104B | |
-12.65% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.02% | 17.89B | |
+8.37% | 14.28B | |
+35.08% | 12.55B |
- Stock Market
- Equities
- 2137 Stock
- News Brii Biosciences Limited
- Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2022